Drugs / RCT2100
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06237335 | Feb 2024 → Aug 2026 overdue | cystic fibrosis | ReCode Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RCT2100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06237335 ↗ |
| Modality | Messenger RNA (mRNA) | “RCT2100 (CFTR mRNA)” NCT06237335 ↗ |
| Route | Inhaled | “administered via oral inhalation using nebulizer” NCT06237335 ↗ |